[go: up one dir, main page]

HK1258331A1 - 弗林蛋白酶敲減和gm-csf增强的(fang)癌症疫苗 - Google Patents

弗林蛋白酶敲減和gm-csf增强的(fang)癌症疫苗

Info

Publication number
HK1258331A1
HK1258331A1 HK19100699.3A HK19100699A HK1258331A1 HK 1258331 A1 HK1258331 A1 HK 1258331A1 HK 19100699 A HK19100699 A HK 19100699A HK 1258331 A1 HK1258331 A1 HK 1258331A1
Authority
HK
Hong Kong
Prior art keywords
furin
knockdown
fang
csf
augmented
Prior art date
Application number
HK19100699.3A
Other languages
English (en)
Inventor
J‧J‧內姆納蒂絲
N‧森澤
P‧B‧梅普爾斯
D‧拉奧
Original Assignee
格蘭達利斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 格蘭達利斯有限公司 filed Critical 格蘭達利斯有限公司
Publication of HK1258331A1 publication Critical patent/HK1258331A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
HK19100699.3A 2009-12-23 2019-01-16 弗林蛋白酶敲減和gm-csf增强的(fang)癌症疫苗 HK1258331A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28968109P 2009-12-23 2009-12-23
US30977710P 2010-03-02 2010-03-02

Publications (1)

Publication Number Publication Date
HK1258331A1 true HK1258331A1 (zh) 2019-11-08

Family

ID=44196113

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100699.3A HK1258331A1 (zh) 2009-12-23 2019-01-16 弗林蛋白酶敲減和gm-csf增强的(fang)癌症疫苗

Country Status (13)

Country Link
US (4) US9132146B2 (zh)
EP (1) EP2515916B1 (zh)
JP (2) JP5553906B2 (zh)
KR (2) KR101548567B1 (zh)
CN (2) CN108295087B (zh)
AR (1) AR081057A1 (zh)
AU (1) AU2010333753B2 (zh)
CA (1) CA2785258A1 (zh)
HK (1) HK1258331A1 (zh)
IL (1) IL220589A0 (zh)
SG (3) SG188160A1 (zh)
TW (2) TW201522632A (zh)
WO (1) WO2011079077A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
US9157084B2 (en) 2009-12-23 2015-10-13 Gradalis, Inc. Furin-knockdown bi-functional RNA
EP2515916B1 (en) 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
US8946186B2 (en) 2010-09-20 2015-02-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University QSOX1 as an anti-neoplastic drug target
US20140141015A1 (en) 2010-09-20 2014-05-22 Douglas Lake QSOX1 as an Anti-Neoplastic Drug Target
WO2013115579A1 (ko) * 2012-01-31 2013-08-08 연세대학교 산학협력단 ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US20160024600A1 (en) * 2013-03-15 2016-01-28 The United States of America, as represented by the Secretary, Department of Health and Human Ser Coincidence reporter gene system
CN105705641B (zh) * 2013-07-18 2021-07-13 弗拉芒区生物技术研究所 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
CA2943640A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
WO2015152609A1 (ko) * 2014-03-31 2015-10-08 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자; 데코린 유전자; ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ; 및 ＦｏｘＰ３ 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물
KR101713407B1 (ko) * 2014-03-31 2017-03-07 연세대학교 산학협력단 아데노바이러스 감염 및 복제가 가능한 흑색종 세포주
CN106661576A (zh) * 2014-04-25 2017-05-10 斯特里克生物公司 用于癌症治疗的多靶向RNAi
US11020455B2 (en) 2015-07-30 2021-06-01 Endor Technologies, S.L Colony stimulating factor for use in pancreatic or colon cancer treatment
WO2017099474A1 (ko) * 2015-12-08 2017-06-15 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자; FLT3L-TRAIL 융합 유전자; ＴＧＦ－β 발현을 억제하는 ｓｈＲＮＡ; 및 HSP 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물
CN105734080A (zh) * 2016-01-30 2016-07-06 山西大学 一种靶向抗癌基因-质粒及其构建方法和应用
WO2019074907A1 (en) * 2017-10-10 2019-04-18 Nantbio, Inc. MODIFIED EC7 CELLS WITH LOW TOXICITY FOR VIRAL PRODUCTION LOADS
CA3107770C (en) 2018-08-16 2023-09-05 Emd Millipore Corporation Closed bioprocessing device
WO2020048942A1 (en) * 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
CN109160888B (zh) * 2018-10-09 2022-03-01 四川医立特生物医药有限公司 一种含脒基的对称化合物及其应用
JP7211139B2 (ja) * 2019-02-14 2023-01-24 日本電信電話株式会社 校閲方法、情報処理装置および校閲プログラム
CN110760477A (zh) * 2019-10-10 2020-02-07 杭州广科安德生物科技有限公司 一种小鼠肝脏高转移肠癌细胞株的建立方法，细胞株和应用
KR20220149505A (ko) 2019-12-03 2022-11-08 누보젠 인코포레이티드 종양 세포 백신
JP2023510853A (ja) 2020-01-13 2023-03-15 グラダリス，インコーポレイティド Ｇｍ－ｃｓｆをコードするポリヌクレオチドと追加薬剤を用いてがんを治療する方法
WO2021146213A1 (en) * 2020-01-13 2021-07-22 Gradalis, Inc. Methods for treating cancers using gm-csf encoding polynucleotide and additional agents
JP2023527791A (ja) * 2020-05-26 2023-06-30 グラダリス，インコーポレイティド ウイルス性呼吸器感染症を治療するための方法
JP6967248B1 (ja) 2020-07-22 2021-11-17 大学共同利用機関法人 高エネルギー加速器研究機構 発振回路および電子機器
WO2022055817A1 (en) * 2020-09-09 2022-03-17 Gradalis, Inc. Composition formulated into inhalable dosage forms for the treatment of lung|tumors
JP2024511321A (ja) * 2021-03-10 2024-03-13 グラダリス，インコーポレイティド 癌を治療するための方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1078093B1 (en) * 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US8791081B2 (en) 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
ATE373724T2 (de) 2000-12-01 2007-10-15 Max Planck Gesellschaft Kleine rns moleküle, die rns-interferenz vermitteln
EP1370696A4 (en) 2001-03-20 2009-04-22 Ortho Clinical Diagnostics Inc EXPRESSION PROFILES AND METHOD OF USE
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050080031A1 (en) 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
WO2003006477A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
US20030144823A1 (en) 2001-11-01 2003-07-31 Fox Jeffrey J. Scale-free network inference methods
AU2002348163A1 (en) 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
AU2003211058A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
DK1540505T3 (da) 2002-08-29 2008-10-13 Gene Network Sciences Inc Systemer og fremgangsmåder til dannelse af biologiske net
ATE462449T1 (de) 2002-10-09 2010-04-15 Central Iowa Health System Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
US20040088116A1 (en) 2002-11-04 2004-05-06 Gene Network Sciences, Inc. Methods and systems for creating and using comprehensive and data-driven simulations of biological systems for pharmacological and industrial applications
KR100774041B1 (ko) 2003-01-17 2007-11-06 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 소간섭 ｒｎａ 유전자 치료
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
WO2005000320A2 (en) 2003-06-27 2005-01-06 Atugen Ag Use of double-stranded ribonucleic acid for inducing cell lysis
WO2005065691A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
US20050146081A1 (en) 2004-01-07 2005-07-07 Maclean David Needle protection device with gauge specific color coding and method for manufacturing thereof
AU2005244958A1 (en) 2004-05-20 2005-12-01 Vegenics Limited Method for inhibiting angiogenesis and/or lymphangiogenesis
US20070224194A1 (en) * 2004-05-20 2007-09-27 Ludwig Institute For Cancer Research Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis
AU2005327517B2 (en) 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
DK1797183T3 (da) 2004-09-02 2012-10-01 Univ Yale Regulering af onkogener med mikrornas
WO2006086838A1 (en) 2005-02-16 2006-08-24 The Council Of The Queensland Institute Of Medical Research Flavivirus replicon constructs for tumour therapy
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
US8916530B2 (en) 2005-11-18 2014-12-23 Gradalis, Inc. Individualized cancer therapy
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
US8758998B2 (en) 2006-11-09 2014-06-24 Gradalis, Inc. Construction of bifunctional short hairpin RNA
US8906874B2 (en) 2006-11-09 2014-12-09 Gradalis, Inc. Bi-functional shRNA targeting Stathmin 1 and uses thereof
US20090163431A1 (en) 2007-02-14 2009-06-25 Ontherex Llc Compositions and methods for modulation of pdx-1
CA2688232A1 (en) * 2007-05-25 2008-12-04 Induce Biologics Inc. A method of enhancing recombinant protein production
WO2009002462A1 (en) 2007-06-22 2008-12-31 The Board Of Trustees Of The Leland Stanford Junior University Pre-mirna loop-modulated target regulation
AU2009271401A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
US20110045534A1 (en) * 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
WO2011053660A2 (en) 2009-10-30 2011-05-05 Gradalis, Inc. Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
US9157084B2 (en) 2009-12-23 2015-10-13 Gradalis, Inc. Furin-knockdown bi-functional RNA
EP2515916B1 (en) 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
US20110286979A1 (en) 2010-05-20 2011-11-24 Gradalis, Inc. CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA)
CA2872930A1 (en) 2012-05-09 2013-11-14 Gradalis, Inc. Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations

Also Published As

Publication number Publication date
US9132146B2 (en) 2015-09-15
AU2010333753B2 (en) 2013-06-13
WO2011079077A1 (en) 2011-06-30
CN102917709A (zh) 2013-02-06
KR20120099503A (ko) 2012-09-10
AR081057A1 (es) 2012-06-06
CA2785258A1 (en) 2011-06-30
EP2515916A1 (en) 2012-10-31
CN102917709B (zh) 2018-04-24
TW201130975A (en) 2011-09-16
JP2014210781A (ja) 2014-11-13
IL220589A0 (en) 2012-08-30
KR101548567B1 (ko) 2015-09-01
US20110262408A1 (en) 2011-10-27
JP2013515731A (ja) 2013-05-09
SG181880A1 (en) 2012-07-30
TW201522632A (zh) 2015-06-16
CN108295087B (zh) 2021-01-15
CN108295087A (zh) 2018-07-20
US20130078279A1 (en) 2013-03-28
SG10201606680QA (en) 2016-10-28
EP2515916A4 (en) 2013-10-23
AU2010333753A1 (en) 2012-07-19
JP5820506B2 (ja) 2015-11-24
US10253331B2 (en) 2019-04-09
KR101589951B1 (ko) 2016-01-29
JP5553906B2 (ja) 2014-07-23
EP2515916B1 (en) 2016-03-09
US20150329873A1 (en) 2015-11-19
US9790518B2 (en) 2017-10-17
KR20140108344A (ko) 2014-09-05
US20180073038A1 (en) 2018-03-15
SG188160A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
HK1258331A1 (zh) 弗林蛋白酶敲減和gm-csf增强的(fang)癌症疫苗
HRP20181493T1 (hr) Konjugati epsilon-polilizin i njihova primjena
EP2624845A4 (en) REINFORCED MSC PREPARATIONS
IL217008A0 (en) Vaccine
GB0905570D0 (en) Combined vaccines
ZA201106702B (en) Sceletium extract and uses thereof
EP2622165A4 (en) COMBINED SYSTEM OF DIFFICULT WHISTLE AND PACKAGING DEFLECTOR
PL2444103T3 (pl) Szczepionka przeciwko rakowi szyjki macicy
GB201006165D0 (en) Vaccine
EP2346531A4 (en) ANTITUMOR VACCINE
GB201003293D0 (en) Cancer vaccine
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB0910751D0 (en) Prostate cancer vaccine
GB201000522D0 (en) Vaccine
GB0912744D0 (en) Methods and uses
WO2011008850A9 (en) H3k27me3 and cancer
EP2446723A4 (en) SCREEN CASE AND ANTENNA KIT THEREOF
EP2408808A4 (en) TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
IL217194A0 (en) Vaccine
AU2014201356B2 (en) Combined measles-malaria vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0903145D0 (en) Medicaments uses and methods
GB0914545D0 (en) Vaccine
GB0901696D0 (en) Presure shield